CAR-T therapy transforms relapsed lymphoma into a race for treatment access
CAR-T therapy offers a lifeline for patients with relapsed blood cancers, but the real challenge is getting the treatment before time and logistics run out.
Yescarta 1 article
Autologous T cells is central to Yescarta, a named therapeutic product whose molecular profile combines axicabtagene ciloleucel with CD19-directed CAR T-cell therapy. The intervention also involves CD28 costimulatory domain, chimeric antigen receptor and large B-cell lymphoma, linking its mechanism to follicular lymphoma and ex vivo T-cell engineering. Accordingly, Yescarta should not be collapsed into CD19-directed CAR T-cell therapy as a broader therapeutic class.